Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

被引：0

作者：

Kavan, P. ^{[1
]}

Rho, H. ^{[1
]}

Probst, S. ^{[2
]}

Abikhzer, G. ^{[2
]}

Rho, Y. S. ^{[3
]}

Barrera, I ^{[1
]}

机构：

[1] McGill Univ, Segal Canc Ctr, Dept Med Oncol, Montreal, PQ, Canada

[2] Jewish Gen Hosp, Div Nucl Med, Montreal, PQ, Canada

[3] Univ Hawaii, John A Burns Sch Med, Honolulu, HI USA

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷

关键词：

neuroendocrine tumor; lutetium; prrt; efficacy; safety;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H21

引用

页码：193 / 193

页数：1

共 43 条

[31] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS) [J].

Swiha, Mina M. ;

Sutherland, Duncan E. K. ;

Sistani, Golmehr ;

Khatami, Alireza ;

Abazid, Rami M. ;

Mujoomdar, Amol ;

Wiseman, Daniele P. ;

Romsa, Jonathan G. ;

Reid, Robert H. ;

Laidley, David T. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) :225-236

[32] Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study [J].

Guo, Wei ;

Wen, Xuejun ;

Chen, Yuhang ;

Zhao, Tianzhi ;

Liu, Jia ;

Tao, Yucen ;

Fu, Hao ;

Wang, Hongjian ;

Xu, Weizhi ;

Pang, Yizhen ;

Zhao, Liang ;

Huang, Jingxiong ;

Xu, Pengfei ;

Guo, Zhide ;

Miao, Weibing ;

Zhang, Jingjing ;

Chen, Xiaoyuan ;

Chen, Haojun .

ACTA PHARMACEUTICA SINICA B, 2025, 15 (02) :707-721

[33] Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs) [J].

Sharma, N. ;

Naraev, B. ;

Engelman, E. ;

Zimmerman, M. B. ;

Bushnell, D. ;

O'Dorisio, T. ;

Halfdanarson, T. .

NEUROENDOCRINOLOGY, 2012, 96 :59-59

[34] The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients A Multicenter Real-Life Study [J].

Akdeniz, Nadiye ;

Kaplan, Muhammet Ali ;

Inanc, Mevlude ;

Uncu, Dogan ;

Ergun, Yakup ;

Kucukoner, Mehmet ;

Demirci, Ayse ;

Sendur, Mehmet Ali Nahit ;

Besiroglu, Mehmet ;

Topcu, Atakan ;

Yerlikaya, Halis ;

Urakci, Zuhat ;

Kilickap, Saadettin ;

Isikdogan, Abdurrahman .

PANCREAS, 2022, 51 (09) :1153-1159

[35] Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide [J].

Delpassand, Ebrahim S. ;

Samarghandi, Amin ;

Mourtada, Jennifer Sims ;

Zamanian, Sara ;

Espenan, Gregory D. ;

Sharif, Roozbeh ;

MacKenzie, Shawn ;

Kosari, Kambiz ;

Barakat, Omar ;

Naqvi, Shagufta ;

Seng, John E. ;

Anthony, Lowell .

THERANOSTICS, 2012, 2 (05) :472-480

[36] Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors [J].

Kobayashi, N. ;

Takano, S. ;

Ito, K. ;

Sugiura, M. ;

Ogawa, M. ;

Takeda, Y. ;

Okubo, N. ;

Suzuki, A. ;

Tokuhisa, M. ;

Kaneta, T. ;

Utsunomiya, D. ;

Hata, M. ;

Inoue, T. ;

Hosono, M. ;

Kinuya, S. ;

Ichikawa, Y. .

JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 :149-149

[37] Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings [J].

Guerci, B. ;

Charbonnel, B. ;

Gourdy, P. ;

Hadjadj, S. ;

Hanaire, H. ;

Marre, M. ;

Verges, B. .

DIABETES & METABOLISM, 2019, 45 (06) :528-535

[38] Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study [J].

von Hessert-Vaudoncourt, Claus ;

Maasberg, Sebastian ;

Begum, Nehara ;

Rinke, Anja ;

Poeppel, Thorsten ;

Sipos, Bence ;

Grohe, Christian ;

Fottner, Christian ;

Stintzing, Sebastian ;

Grabowski, Patricia ;

German NET Registry .

MEDICINE, 2025, 104 (11)

[39] Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy [J].

De Silva, Madhawa K. ;

Chan, David L. H. ;

Bernard, Elizabeth J. ;

Conner, Alice J. ;

Mascall, Sophie L. ;

Bailey, Dale L. ;

Roach, Paul J. ;

Clarke, Stephen J. ;

Diakos, Connie I. ;

Pavlakis, Nick ;

Schembri, Geoff .

PANCREAS, 2024, 53 (07) :e560-e565

[40] Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors [J].

Bessac, Darejan Mamulashvili ;

Baltzinger, Philippe ;

Poterszman, Nathan ;

Van, Floriane Pham ;

Collen, Cedric ;

Malouf, Gabriel G. ;

Ouvrard, Eric ;

Kaseb, Ashjan ;

Porot, Clemence ;

Ben Abdelghani, Meher ;

Addeo, Pietro ;

Mertz, Luc ;

Goichot, Bernard ;

Imperiale, Alessio .

ENDOCRINE, 2025, 87 (03) :1333-1341

← 1 2 3 4 5 →